Case Reports
doi: 10.1016/j.jdcr.2020.09.003.
eCollection 2020 Dec.
Resolution of pretibial myxedema with teprotumumab in a patient with Graves disease
Affiliations
- PMID: 33294564
- PMCID: PMC7701010
- DOI: 10.1016/j.jdcr.2020.09.003
Item in Clipboard
Case Reports
Resolution of pretibial myxedema with teprotumumab in a patient with Graves disease
JAAD Case Rep.
.
No abstract available
Figures
Pretibial myxedema before and after treatment with teprotumumab. A, Patient's pretibial myxedema at its worst before therapy. B, Patient's pretibial myxedema 14 months after treatment with electrocautery and rituximab infusions. (Previously published.4) C, Patient's pretibial myxedema 1 week after fourth infusion of teprotumumab.
Similar articles
-
Graves' disease complicated by concurrent thyroid eye disease and pretibial myxedema successfully treated with teprotumumab.Clin Case Rep. 2022 Nov 19;10(11):e6621. doi: 10.1002/ccr3.6621. eCollection 2022 Nov. Clin Case Rep. 2022. PMID: 36415714 Free PMC article.
-
Orbital decompression in Graves' ophthalmopathy associated with pretibial myxedema.J Endocrinol Invest. 1993 Jun;16(6):433-7. doi: 10.1007/BF03348875. J Endocrinol Invest. 1993. PMID: 8370919
-
Pretibial myxedema in a euthyroid patient: a case report.Thyroid Res. 2021 Mar 1;14(1):4. doi: 10.1186/s13044-021-00096-z. Thyroid Res. 2021. PMID: 33648506 Free PMC article.
-
Pretibial myxedema with Graves' disease: a case report and review of Japanese literature.J Dermatol. 1998 Apr;25(4):264-8. doi: 10.1111/j.1346-8138.1998.tb02394.x. J Dermatol. 1998. PMID: 9609987 Review.
-
Pretibial myxedema: pathophysiology and treatment options.Am J Clin Dermatol. 2005;6(5):295-309. doi: 10.2165/00128071-200506050-00003. Am J Clin Dermatol. 2005. PMID: 16252929 Review.
Cited by
-
[An integrated approach to the treatment of pretibial myxedema based on pulse therapy with prednisolone and electrical neuromyostimulation (FREMS-therapy) in a patient with Graves' disease and thyroid eye disease].Probl Endokrinol (Mosk). 2023 Aug 30;69(4):32-37. doi: 10.14341/probl12888. Probl Endokrinol (Mosk). 2023. PMID: 37694865 Free PMC article. Russian.
-
Therapeutic IGF-I receptor inhibition alters fibrocyte immune phenotype in thyroid-associated ophthalmopathy.Proc Natl Acad Sci U S A. 2021 Dec 28;118(52):e2114244118. doi: 10.1073/pnas.2114244118. Proc Natl Acad Sci U S A. 2021. PMID: 34949642 Free PMC article.
-
Dermatologic manifestations of thyroid disease: a literature review.Front Endocrinol (Lausanne). 2023 May 12;14:1167890. doi: 10.3389/fendo.2023.1167890. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37251685 Free PMC article. Review.
-
Infusion Center Guidelines for Teprotumumab Infusions: Informed Consent, Safety, and Management of Side Effects.J Infus Nurs. 2021 Nov-Dec 01;44(6):331-338. doi: 10.1097/NAN.0000000000000446. J Infus Nurs. 2021. PMID: 34753152 Free PMC article.
-
A case of pretibial myxedema treated with teprotumumab.JAAD Case Rep. 2021 Sep 1;16:134-136. doi: 10.1016/j.jdcr.2021.08.026. eCollection 2021 Oct. JAAD Case Rep. 2021. PMID: 34604488 Free PMC article. No abstract available.
References
-
- Fatourechi V. Pretibial myxedema. Am J Clin Dermatol. 2005;6(5):295–309. - PubMed
-
- Heymann W.R. Teprotumumab: an eye-opening advance for pretibial myxedema? Dermatology World Insights and Inquiries. 2017 https://www.aad.org/dw/dw-insights-and-inquiries/medical-dermatology/tep... Accessed October 24, 2020. Available at:
-
- Ghazi E.R., Heymann W.R. Pretibial myxedema. In: Lebwohl M.G., Heymann W.R., Berth-Jones J., Coulson I., editors. Treatment of Skin Disease. Elsevier; London, Chapter 202: 2018. pp. 668–671.
-
- Alia E., Feit E.J., Levitt J.O. Electrosurgical debulking of pretibial myxedema of the foot. Dermatol Online J. 2019;25(2) 13030/qt4hb7q330. - PubMed
-
- Schwartz K.M., Fatourechi V., Ahmed D.D., Pond G.R. Dermopathy of Graves' disease (pretibial myxedema): long-term outcome. J Clin Endocrinol Metab. 2002;87(2):438–446. - PubMed
Publication types
LinkOut - more resources
Full Text Sources